Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.10), $0.13 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $103 million versus the consensus estimate of $217.65 thousand.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.